LIFEPharma (Life Pharma FZE)
Growth Score40DXBi Rank173Heat Score100Life Pharma FZE
UAE's only USFDA-approved pharmaceutical manufacturer, part of the VPS Health group.
Media
Preview imagery published alongside each story, linking back to the original.
Overview
Growth Score
Steady
Heat Score
Trending up
Details
- Operating Status
- Active
- Company Type
- Private (subsidiary of VPS Health / VPS Healthcare group)
- Headquarters
- Jebel Ali Free Zone, Dubai, UAE (per company site; new manufacturing platform under development at KEZAD, Abu Dhabi)
- Founded
- 2011
- Company Size
- 501-1000 employees
- Revenue
- $25M-$50M (per Datanyze third-party estimate; unverified against primary source)
- Website
- lifepharmafze.com
Products & Services
Avilife (Favipiravir 200mg)
Antiviral tablet, developed for COVID-19 treatment
Antijoin
Anti-adhesion solution (Hydroxyethyl starch + Sodium hyaluronate) used in surgery
Clopimet (Clopidogrel 75mg)
Anticoagulant/antiplatelet tablet
Gastrex (Simethicone 42mg)
Antiflatulent
Loralife (Loratadine 10mg)
Antihistamine
Telife (Fexofenadine HCl)
Antihistamine
Lipira (Atorvastatin)
Antihyperlipidemic (cholesterol-lowering) tablet
Rosulife (Rosuvastatin)
Antihyperlipidemic (cholesterol-lowering) tablet
Equigene Therapeutics
LIFEPharma-launched gene/cell therapy biotech platform targeting hemophilia, thalassemia and sickle cell disease
People
Technology
No technology or web presence data on file yet.
Financials
Funding rounds
Projects
LIFEPharma - AD Ports Group Kezad Manufacturing Platform
LIFEPharma signed an MOU with AD Ports Group during Make it in the Emirates 2026 to build a Dh700m ($191m) advanced pharmaceutical manufacturing platform at Khalifa Economic Zones Abu Dhabi (Kezad), comprising a Dh300m vaccine fill-and-finish facility, Dh200m oncology manufacturing, and Dh200m for peptides/biologics/injectables. Projected to add ~Dh2bn to GDP and create 1,000+ jobs. Signed by Capt. Mohamed Juma Al Shamisi (AD Ports Group CEO), Dr. Shamsheer Vayalil and Omran Al Khoori (VPS Health) and Abdullah Al Hameli (AD Ports).
$191M
May 5, 2026
LIFEPharma - Ajman Bank Strategic Financing Agreement
Ajman Bank signed a strategic financing agreement with LIFEPharma at Make it in the Emirates 2026 to support LIFEPharma's expansion roadmap, including advanced manufacturing, complex therapies (injectables/specialized formulations), IP acquisition, product development, and technology adoption. Specific financing amount was not disclosed in reporting.
May 5, 2026
Equigene Therapeutics Gene Therapy Initiative Launch
LIFEPharma launched Equigene Therapeutics, an AED100m ($27.2m) region-first cell-and-gene-therapy biotech platform targeting rare inherited blood disorders (hemophilia A and B, thalassemia, sickle cell disease), led by hematologist Prof. Alok Srivastava, in partnership with Burjeel Holdings' Center for Research on Rare Blood Disorders (Prof. Khaled Musallam) as part of a UAE-India healthcare corridor collaboration. Targeting a 3-5 year go-to-market timeline.
$27M
May 5, 2026
LIFEPharma - Apotex 10-Year Generic Drug Export Agreement
LIFEPharma signed a 10-year deal with Canada's Apotex to manufacture up to 120 million tablets annually of nine generic medications (covering conditions including ALS, Parkinson's, Hepatitis B, seizures, and resistant bacterial infections) for export to Canada, making LIFEPharma the first UAE company to export generics to the North American market. Quoted: Dr. Shamsheer Vayalil (VPS Healthcare) and Jeff Watson (Apotex President & CEO).
Oct 9, 2019
Similar Companies
Official Channels
Where LIFEPharma (Life Pharma FZE) publishes directly. Each link is checked for the correct platform and profile format.
A tick means the link resolves to a valid company profile URL on that platform. It does not confirm the account is operated by LIFEPharma (Life Pharma FZE) — that requires a signal only the platform or the company can give, so DXBi does not claim it.
Press & Announcements
Every item links back to its original source. Announcements are only marked as coming from LIFEPharma (Life Pharma FZE) when the link resolves to the company's own domain.



